Institute for Follicular Lymphoma Innovation
Tracked across 1 events · 6 articles · First seen Jul 20, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
PeproMene Bio announced the publication in The Lancet of results from its Phase 1 clinical trial of PMB-CT01, a first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial…
Impact: IFLI provided up to $11 million in funding to support the clinical development of PMB-CT01. The positive results validate its investment and support its mission to advance treatments for follicular lymphoma.
Jul 20, 2026 · 6 articles
60
Institute for Follicular Lymphoma Innovation committed funding PeproMene BioPeproMene Bio publishes...
ERGEN INTELLIGENCE
Track Institute for Follicular Lymphoma Innovation live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard